undamentalytics Newsletter

Optimizerx Corp income statement

In fiscal 2025, Optimizerx Corp reported revenue of $109m, up 18.8% on the year before, operating income of $11.7m (a 10.7% margin) and net income of $5.1m, or $0.27 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Optimizerx Corp: income statement, annual
Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0125778122125436162729210999
Cost of revenue————————9919262329333626
Gross profit——233446121524363943597472
Research and development————————020———00—
Selling, general and administrative———————————2833————
General and administrative—000—————————————
Operating income−2−1−0−0−1−1−2−20−4−20−12−26−141211
Interest expense−010000———————1655
Income before tax———−0−1−1−2−20−4−20−11−25−1977
Income tax———000———−1———−8122
Net income−2−2−0−0−1−1−2−20−3−20−11−18−2055
Diluted EPS———−$0.06−$0.12—−$0.05−$0.21$0.02−$0.23−$0.15$0.02−$0.64−$1.03−$1.10$0.27$0.24
Diluted shares (average)——6m7m8m8m10m10m12m13m15m18m18m17m18m19m19m
EBITDA−2−1−0−0−1−0−1−20−2−02−10−24−91615

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: OPRX vs SOPHCCLD vs OPRXAMWL vs OPRX

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Optimizerx Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Optimizerx Corp.